Ipilimumab and Nivolumab for Treatment of Eyelid Spindle Cell Melanoma

被引：2
|
作者：
Shoji, Marissa K. [1 ,2 ]
Rong, Andrew J. [1 ,2 ]
机构：
[1] Univ Miami, Bascom Palmer Eye Inst, Miller Sch Med, Miami, FL USA
[2] Univ Miami, Bascom Palmer Eye Inst, Miller Sch Med, 900 NW 17th St, Miami, FL 33136 USA
来源：
AMERICAN JOURNAL OF OPHTHALMOLOGY | 2023年 / 250卷
关键词：
D O I：
10.1016/j.ajo.2023.02.010
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：E1 / E2
页数：2
相关论文
共 50 条
  • [41] Partial Remission of advanced Melanoma by Combination Therapy with Nivolumab and Trametinib after Treatment Failure with Ipilimumab plus Nivolumab
    Zaremba, A.
    Chorti, E.
    Jockenhoefer, F.
    Albrecht, M.
    Placke, J. M.
    Knispel, S.
    Schadendorf, D.
    Hadaschik, E.
    Roesch, A.
    Ugurel, S.
    Zimmer, L.
    Livingstone, E.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 38 - 38
  • [42] International experience of ipilimumab and nivolumab in patients with advanced melanoma
    Serra-Bellver, P.
    Versluis, J. M.
    Oberoi, H. K.
    Slattery, T. D.
    Khan, Y.
    Patrinelly, J. R.
    da Silva, I. Pires
    Martinez-Vila, C.
    Cook, N.
    Graham, D. M.
    Zhou, C.
    Gupta, A.
    Fernandez, A. M. Arance
    Johnson, D. B.
    Long, G. V.
    Pickering, L.
    Larkin, J.
    Blank, C. U.
    Lorigan, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S747 - S748
  • [43] Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
    Blank, Christian U.
    Lucas, Minke W.
    Scolyer, Richard A.
    van de Wiel, Bart A.
    Menzies, Alexander M.
    Lopez-Yurda, Marta
    Hoeijmakers, Lotte L.
    Saw, Robyn P. M.
    Lijnsvelt, Judith M.
    Maher, Nigel G.
    Pulleman, Saskia M.
    Gonzalez, Maria
    Torres Acosta, Alejandro
    van Houdt, Winan J.
    Lo, Serigne N.
    Kuijpers, Anke M. J.
    Spillane, Andrew
    Klop, W. Martin C.
    Pennington, Thomas E.
    Zuur, Charlotte L.
    Shannon, Kerwin F.
    Seinstra, Beatrijs A.
    Rawson, Robert V.
    Haanen, John B. A. G.
    Ch'ng, Sydney
    Naipal, Kishan A. T.
    Stretch, Jonathan
    van Thienen, Johannes V.
    Rtshiladze, Michael A.
    Wilgenhof, Sofie
    Kapoor, Rony
    Meerveld-Eggink, Aafke
    Grijpink-Ongering, Lindsay G.
    van Akkooi, Alexander C. J.
    Reijers, Irene L. M.
    Gyorki, David E.
    Gruenhagen, Dirk J.
    Speetjens, Frank M.
    Vliek, Sonja B.
    Placzke, Joanna
    Spain, Lavinia
    Stassen, Robert C.
    Amini-Adle, Mona
    Lebbe, Celeste
    Faries, Mark B.
    Robert, Caroline
    Ascierto, Paolo A.
    van Rijn, Rozemarijn
    van den Berkmortel, Franchette W. P. J.
    Piersma, Djura
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (18): : 1696 - 1708
  • [44] GASTROINTESTINAL EVENTS IN MELANOMA PATIENTS TREATED WITH IPILIMUMAB AND NIVOLUMAB
    Irwin, D.
    Davis, B. M.
    Bell, J.
    Galaznik, A.
    Garcia-Ribas, I
    VALUE IN HEALTH, 2018, 21 : S14 - S14
  • [45] Long-term results with nivolumab and ipilimumab in melanoma
    Giacco, Vincenzo
    NATURE CANCER, 2025, 6 (03) : 407 - 407
  • [46] Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma
    Augustin, Ryan C.
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 443 - +
  • [47] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Lao, Christopher D.
    Cowey, C. Lance
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Ferrucci, Pier Francesco
    Smylie, Michael
    Butler, Marcus O.
    Hill, Andrew
    Marquez-Rodas, Ivan
    Haanen, John B. A. G.
    Guidoboni, Massimo
    Maio, Michele
    Schoffski, Patrick
    Carlino, Matteo S.
    Lebbe, Celeste
    McArthur, Grant
    Ascierto, Paolo A.
    Daniels, Gregory A.
    Long, Georgina, V
    Bas, Tuba
    Ritchings, Corey
    Larkin, James
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
  • [48] HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    Moshyk, A.
    Kotapati, S.
    VALUE IN HEALTH, 2019, 22 : S72 - S73
  • [49] Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
    Reichert, Constance
    Baldini, Capucine
    Mezghani, Sarah
    Maubec, Eve
    Longvert, Christine
    Mortier, Laurent
    Quereux, Gaelle
    Jannic, Arnaud
    Machet, Laurent
    de Quatrebarbes, Julie
    Nardin, Charlee
    Beneton, Nathalie
    Amini Adle, Mona
    Funck-Brentano, Elisa
    Descamps, Vincent
    Hachon, Lorry
    Malissen, Nausicaa
    Baroudjian, Barouyr
    Brunet-Possenti, Florence
    CANCERS, 2023, 15 (17)
  • [50] Ipilimumab after nivolumab therapy for melanoma patients in Asia
    Tsutsumida, A.
    Yamazaki, N.
    Takahashi, A.
    Namikawa, K.
    ANNALS OF ONCOLOGY, 2016, 27
12345